Cargando…
Public funding for transformative drugs: the case of sofosbuvir
The approval of sofosbuvir (Sovaldi) in 2013 transformed chronic hepatitis C virus (HCV) care, but its high cost was criticized in part because of reports of substantial public involvement in its development. We developed a methodology to assess the public’s contribution through the National Institu...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528745/ https://www.ncbi.nlm.nih.gov/pubmed/33011345 http://dx.doi.org/10.1016/j.drudis.2020.09.024 |